Can a special PET scan unlock a new way to treat Hard-to-Treat upper GI cancers?

NCT ID NCT05214820

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether a special PET scan using a tracer called 68Ga-PSMA can identify patients with advanced upper digestive tract cancers (like stomach or esophageal cancer) who might be eligible for a type of targeted radiation therapy called endoradiotherapy. The researchers will scan 20 adults with active cancer to see if their tumors take up enough of the tracer. The goal is not to treat the cancer directly, but to find out who could benefit from future treatment with a radioactive drug called 177Lu-PSMA.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

68Ga-PSMA (a radioactive tracer for PET imaging)

What this could lead to

If successful, this could show that PSMA PET scans can select patients who might benefit from targeted radiation therapy, opening a new treatment path for upper GI cancers.

What could go wrong

This is a small, early-phase study (20 participants) focused on imaging, not treatment. It only checks eligibility for future therapy, so direct patient benefit is uncertain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC ADENOCARCINOMA OF THE PANCREAS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bile duct adenocarcinoma esophageal adenocarcinoma gastric adenocarcinoma pancreatic adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • CIUSSS de l'Estrie- CHUS Hospital

    Sherbrooke, Quebec, J1H 5N4, Canada